To evaluate if LIV-1 expression is associated with clinical progression of human prostate cancer, we raised polyclonal antibodies by immunizing rabbits with a KLH-conjugated LIV-1 peptide. This evidence concerns the gene SLC39A6 and Familial prostate cancer.